======= YY1 =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: YY1
  * **<color #00a2e8>Official Name</color>**: YY1 transcription factor
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=7528|7528]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/P25490|P25490]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=YY1&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20YY1|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/600013|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**:  YY1 is a ubiquitously distributed transcription factor belonging to the GLI-Kruppel class of zinc finger proteins. The protein is involved in repressing and activating a diverse number of promoters.  YY1 may direct histone deacetylases and histone acetyltransferases to a promoter in order to activate or repress the promoter, thus implicating histone modification in the function of YY1. [provided by RefSeq, Jul 2008]. 
  * **<color #00a2e8>UniProt Summary</color>**:  Multifunctional transcription factor that exhibits positive and negative control on a large number of cellular and viral genes by binding to sites overlapping the transcription start site. Binds to the consensus sequence 5'-CCGCCATNTT-3'; some genes have been shown to contain a longer binding motif allowing enhanced binding; the initial CG dinucleotide can be methylated greatly reducing the binding affinity. The effect on transcription regulation is depending upon the context in which it binds and diverse mechanisms of action include direct activation or repression, indirect activation or repression via cofactor recruitment, or activation or repression by disruption of binding sites or conformational DNA changes. Its activity is regulated by transcription factors and cytoplasmic proteins that have been shown to abrogate or completely inhibit YY1-mediated activation or repression. For example, it acts as a repressor in absence of adenovirus E1A protein but as an activator in its presence. Acts synergistically with the SMAD1 and SMAD4 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression (PubMed:15329343). Binds to SMAD binding elements (SBEs) (5'- GTCT/AGAC-3') within BMP response element (BMPRE) of cardiac activating regions. May play an important role in development and differentiation. Proposed to recruit the PRC2/EED-EZH2 complex to target genes that are transcriptional repressed. Involved in DNA repair. In vitro, binds to DNA recombination intermediate structures (Holliday junctions). Plays a role in regulating enhancer activation (PubMed:28575647). {ECO:0000269|PubMed:15329343, ECO:0000269|PubMed:24326773, ECO:0000269|PubMed:25787250, ECO:0000269|PubMed:28575647}.

<button type='default' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
No Pfam Domain information is available for this gene.
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|response to prostaglandin F|
|negative regulation of cell growth involved in cardiac muscle cell development|
|negative regulation of pri-miRNA transcription by RNA polymerase II|
|negative regulation of interferon-beta production|
|four-way junction DNA binding|
|response to UV-C|
|Ino80 complex|
|negative regulation of cardiac muscle cell differentiation|
|regulation of cell growth involved in cardiac muscle cell development|
|negative regulation of cardiocyte differentiation|
|negative regulation of heart growth|
|negative regulation of cardiac muscle tissue growth|
|enhancer sequence-specific DNA binding|
|negative regulation of cardiac muscle hypertrophy|
|PcG protein complex|
|negative regulation of muscle hypertrophy|
|response to prostaglandin|
|negative regulation of organ growth|
|proximal promoter sequence-specific DNA binding|
|negative regulation of cardiac muscle tissue development|
|regulation of cardiac muscle cell differentiation|
|negative regulation of striated muscle cell differentiation|
|regulation of pri-miRNA transcription by RNA polymerase II|
|negative regulation of type I interferon production|
|regulation of interferon-beta production|
|negative regulation of striated muscle tissue development|
|negative regulation of muscle organ development|
|regulation of cardiocyte differentiation|
|negative regulation of muscle tissue development|
|SMAD binding|
|negative regulation of muscle cell differentiation|
|regulation of cardiac muscle hypertrophy|
|regulation of cardiac muscle tissue growth|
|regulation of muscle hypertrophy|
|regulation of heart growth|
|regulation of cardiac muscle tissue development|
|cellular response to UV|
|response to fatty acid|
|regulation of muscle adaptation|
|regulation of organ growth|
|double-strand break repair via homologous recombination|
|recombinational repair|
|RNA polymerase II distal enhancer sequence-specific DNA binding|
|regulation of striated muscle cell differentiation|
|negative regulation of developmental growth|
|nuclear matrix|
|camera-type eye morphogenesis|
|cellular response to light stimulus|
|regulation of type I interferon production|
|regulation of striated muscle tissue development|
|regulation of muscle tissue development|
|regulation of muscle organ development|
|response to UV|
|eye morphogenesis|
|regulation of muscle cell differentiation|
|cellular response to interleukin-1|
|cellular response to radiation|
|double-strand break repair|
|negative regulation of cell growth|
|response to interleukin-1|
|transcription factor complex|
|anterior/posterior pattern specification|
|RNA localization|
|transcription regulatory region DNA binding|
|DNA recombination|
|regulation of muscle system process|
|nuclear chromatin|
|transcription corepressor activity|
|negative regulation of growth|
|DNA-binding transcription repressor activity, RNA polymerase II-specific|
|sensory organ morphogenesis|
|negative regulation of cytokine production|
|protein deubiquitination|
|transcription coactivator activity|
|protein modification by small protein removal|
|response to light stimulus|
|camera-type eye development|
|cellular response to environmental stimulus|
|cellular response to abiotic stimulus|
|regulation of developmental growth|
|regionalization|
|negative regulation of cell development|
|response to acid chemical|
|eye development|
|visual system development|
|sensory system development|
|regulation of cell growth|
|sequence-specific DNA binding|
|pattern specification process|
|response to radiation|
|RNA polymerase II proximal promoter sequence-specific DNA binding|
|DNA repair|
|spermatogenesis|
|sensory organ development|
|male gamete generation|
|regulation of system process|
|regulation of growth|
|DNA-binding transcription factor activity|
|gamete generation|
|regulation of cytokine production|
|negative regulation of cell differentiation|
|DNA metabolic process|
|cellular response to DNA damage stimulus|
|multicellular organismal reproductive process|
|sexual reproduction|
|zinc ion binding|
|multicellular organism reproduction|
|response to lipid|
|negative regulation of transcription by RNA polymerase II|
|response to hormone|
|regulation of cell development|
|negative regulation of developmental process|
|animal organ morphogenesis|
|protein modification by small protein conjugation or removal|
|multi-organism reproductive process|
|cellular response to cytokine stimulus|
|chromosome organization|
|response to cytokine|
|response to abiotic stimulus|
|negative regulation of transcription, DNA-templated|
|negative regulation of multicellular organismal process|
|positive regulation of transcription by RNA polymerase II|
|negative regulation of nucleic acid-templated transcription|
|negative regulation of RNA biosynthetic process|
|proteolysis|
|negative regulation of RNA metabolic process|
|negative regulation of cellular macromolecule biosynthetic process|
|RNA binding|
|reproductive process|
|reproduction|
|negative regulation of nucleobase-containing compound metabolic process|
|DNA binding|
|negative regulation of macromolecule biosynthetic process|
|response to endogenous stimulus|
|negative regulation of cellular biosynthetic process|
|positive regulation of transcription, DNA-templated|
|negative regulation of biosynthetic process|
|response to oxygen-containing compound|
|DNA-binding transcription factor activity, RNA polymerase II-specific|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|cellular response to stress|
|negative regulation of gene expression|
|positive regulation of RNA metabolic process|
|regulation of cell differentiation|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|positive regulation of biosynthetic process|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='primary' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp488|Hippuristanol 0.12μM R08 exp488]]|-2.44|
|[[:results:exp7|Bortezomib 0.05μM R00 exp7]]|-2.43|
|[[:results:exp68|Clomiphene 4.4μM R02 exp68]]|-2.38|
|[[:results:exp98|BI-6727 0.04μM R03 exp98]]|-2.36|
|[[:results:exp454|Bafilomycin-A1 0.009μM R08 exp454]]|-2.28|
|[[:results:exp294|Nutlin-3A 1.6μM R06 exp294]]|-2.25|
|[[:results:exp350|Deferoxamine 11μM R07 exp350]]|-2.24|
|[[:results:exp489|Hippuristanol 0.12μM R08 exp489 no dilution day6]]|-2.2|
|[[:results:exp33|Rotenone 2μM R00 exp33]]|-2.11|
|[[:results:exp227|Cryptotanshinone 12μM R05 exp227]]|-2.07|
|[[:results:exp527|Tanespimycin 14μM R08 exp527]]|-2.02|
|[[:results:exp535|Trimetrexate 0.03μM R08 exp535]]|-1.94|
|[[:results:exp469|CFI-400945 25μM R08 exp469]]|-1.86|
|[[:results:exp374|Latrunculin-B 10μM R07 exp374]]|-1.73|
|[[:results:exp390|Pifithrin-alpha 20μM R07 exp390]]|1.81|
|[[:results:exp499|LY2090314 0.003μM R08 exp499]]|1.86|
|[[:results:exp355|Dinaciclib 0.007μM R07 exp355]]|1.9|
|[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|1.91|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
^Gene^Correlation^
|[[:human genes:p:prim1|PRIM1]]|0.475|
|[[:human genes:c:chd4|CHD4]]|0.419|
|[[:human genes:r:rps3a|RPS3A]]|0.409|
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 100/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|1/1|
|909776.0|0/1|
|bile duct|1/28|
|blood|4/28|
|bone|2/25|
|breast|3/33|
|central nervous system|5/56|
|cervix|0/4|
|colorectal|4/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|3/15|
|kidney|7/21|
|liver|3/20|
|lung|5/75|
|lymphocyte|2/14|
|ovary|4/26|
|pancreas|0/24|
|peripheral nervous system|6/16|
|plasma cell|8/15|
|prostate|0/1|
|skin|4/24|
|soft tissue|1/7|
|thyroid|1/2|
|upper aerodigestive|2/22|
|urinary tract|3/29|
|uterus|2/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 1238
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 7.73 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='YY1 Expression in NALM6 Cells: 7.73'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>